When compared with other biologic therapies, patients with psoriasis receiving IL-23 inhibitors had a lower risk for inflammatory arthritis or psoriatic arthritis development.
Tumor necrosis factor inhibitor drugs industry is projected to witness a CAGR of 2.2% during the period 2024-2032. This growth can be attributed to advancements in biotechnology and drug ...